TY  - JOUR
AB  - Nearly 90 clinicians and researchers from around the world attended the first IMPROVE 2022 International Meeting on Pathway-Related Obesity. Delegates attended in person or online from across Europe, Argentina and Israel to hear the latest scientific and clinical developments in hyperphagia and severe, early-onset obesity, and set out a vision of excellence for the future for improving the diagnosis, treatment, and care of patients with melanocortin-4 receptor (MC4R) pathway-related obesity. The meeting co-chair Peter Kühnen, Charité Universitätsmedizin Berlin, Germany, indicated that change was needed with the rapidly increasing prevalence of obesity and the associated complications to improve the understanding of the underlying mechanisms and acknowledge that monogenic forms of obesity can play an important role, providing insights that can be applied to a wider group of patients with obesity. World-leading experts presented the latest research and led discussions on the underlying science of obesity, diagnosis (including clinical and genetic approaches such as the role of defective MC4R signalling), and emerging clinical data and research with targeted pharmacological approaches. The aim of the meeting was to agree on the questions that needed to be addressed in future research and to ensure that optimised diagnostic work-up was used with new genetic testing tools becoming available. This should aid the planning of new evidence-based treatment strategies for the future, as explained by co-chair Martin Wabitsch, Ulm University Medical Center, Germany.
AU  - Kühnen, P.*
AU  - Argente, J.*
AU  - Clément, K.*
AU  - Dollfus, H.*
AU  - Dubern, B.*
AU  - Farooqi, S.*
AU  - de Groot, C.*
AU  - Grüters, A.*
AU  - Holm, J.C.*
AU  - Hopkins, M.*
AU  - Kleinendorst, L.*
AU  - Körner, A.*
AU  - Meeker, D.*
AU  - Rydén, M.*
AU  - von Schnurbein, J.*
AU  - Tschöp, M.H.
AU  - Yeo, G.S.H.*
AU  - Zorn, S.*
AU  - Wabitsch, M.*
C1  - 70499
C2  - 55639
TI  - IMPROVE 2022 International Meeting on pathway-related obesity: Vision of excellence.
JO  - Clin. Obes.
VL  - 14
PY  - 2024
SN  - 1758-8103
ER  - 

TY  - JOUR
AB  - Drug therapy in patients who have undergone bariatric surgery is challenging. We aimed to investigate the patients' perspective on their drug therapy. This should allow deriving tailored measures to better support patients and their healthcare professionals with drug therapy after bariatric surgery. We conducted a quantitative telephone-based interview study with patients who have undergone bariatric surgery. The interview consisted of assessments in three parts: (i) current drug therapy: prescription, administration and adherence, (ii) changes after bariatric surgery and (iii) adverse events. (i) The 105 enrolled patients were taking a median of 10 (range: 3-30) drugs. In 1017 of 1080 drugs (94%), expectations in drug effectiveness were (rather) met. Of the 105 patients, 27% reported difficulties in drug administration, 44% forgot to take their drugs at least one time and 20% reported deviations from the prescription. (ii) Sixteen percent of the patients observed changes in drug effectiveness or tolerability-additionally to therapy adjustment by physicians. (iii) Seventy-four percent recognised at least one adverse event right before and/or after bariatric surgery, most frequently in gastrointestinal disorders. Patients who have undergone bariatric surgery have to deal with many difficulties in drug handling and adverse events. Our study emphasises the need for better and more individual support for patients with their drug therapy after bariatric surgery and, therefore, suggests a multidisciplinary approach that includes pharmacists. The stronger involvement of the patients' perspective seems to be a valuable source in research and practice.
AU  - Schiek, S.*
AU  - Drotleff, M.*
AU  - Schueler, D.*
AU  - Heinitz, K.*
AU  - Frisch, A.*
AU  - Selig, L.*
AU  - Remane, Y.*
AU  - Dietrich, A.*
AU  - Blüher, M.
AU  - Bertsche, T.*
C1  - 70617
C2  - 55772
CY  - 111 River St, Hoboken, Nj 07030 Usa
TI  - Patients' perspective on their drug therapy after bariatric surgery: A quantitative, cross-sectional interview study.
JO  - Clin. Obes.
PB  - Wiley
PY  - 2024
SN  - 1758-8103
ER  -